MARLBOROUGH, Mass., Jan. 12, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that Chief Executive Officer & President Burke T. Barrett will present at the 23rd Annual ICR Conference, being held virtually January 11-14, 2021.
MARLBOROUGH, Mass., Jan. 11, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that it has expanded its existing French distribution partnership agreement with MicroPort CRM in France to include both Spain and Portugal.
CardioFocus® Announces 10,000 Patients Treated Worldwide
MARLBOROUGH, Mass., June 16, 2020 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that more than 10,000 patients worldwide have been treated with the HeartLight® Endoscopic Ablation System.
MARLBOROUGH, Mass., June 16, 2020 /PRNewswire/ — CardioFocus, Inc., today announced that the first U.S. patients have been treated commercially with the recently-approved HeartLight X3 Endoscopic Ablation System. The revolutionary cardiac ablation technology is designed to treat drug refractory, symptomatic paroxysmal atrial fibrillation (AFib), the most common heart rhythm disorder.
MARLBOROUGH, Mass., May 12, 2020 /PRNewswire/ — CardioFocus, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the next-generation HeartLight X3 Endoscopic Ablation System for the treatment of drug refractory symptomatic paroxysmal atrial fibrillation (PAF).
MARLBOROUGH, Mass., February 4, 2020 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that the company has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for the HeartLight X3 Endoscopic Ablation System for the treatment of AFib. This supplement […]
CardioFocus® Names Burke T. Barrett as Chief Executive Officer
MARLBOROUGH, Mass., January 22, 2020 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that the Company’s Board of Directors has promoted Burke T. Barrett to the position of Chief Executive Officer (CEO), effective January 19, 2020. Mr. Barrett previously served as CardioFocus’ President and Chief […]
CardioFocus® Treats First Patients with HeartLight® Endoscopic Ablation System in France
MARLBOROUGH, Mass., October 29, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that the first patients in France have been treated at the Centre Hospitalier Régional Universitaire (CHRU) of Nancy with the HeartLight® Endoscopic Ablation System as part of an exclusive distribution partnership with MicroPort CRM […]
CardioFocus® Launches 100th HeartLight® Center Worldwide
MARLBOROUGH, Mass., June 18, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that the HeartLight® Endoscopic Ablation System is now offered at more than 100 hospitals worldwide.
CardioFocus® Secures $55 Million In Financing
MARLBOROUGH, Mass., May 28, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the completion of a $55 million round of financing.